Morinaga Milk Industry Co., Ltd.

The Circle for the Promotion of Science and Engineering

Olympus Corporation

Showa University

Kazuhiro Nagata

Hiroyuki Fukuyama

Morio Kuboyama

Minoru Saito

Wataru Nakao

Eiji Takahashi

Kenji Ono

Takashi Itoh

Katsuhiro Ogasa

Tsutomu Kudo

Taro Nagasawa

Joji Ono

Norichika Fukushima

Kazuyoshi Doi

Michiko Miyazaki

Daijiro Kubota

Yuichiro Tomisawa

Yasunori Oki

Misa Mori

Takuya Kanemitsu

According to one aspect, a balloon-equipped treatment tool for an endoscope includes a balloon, and a sheath connected to a proximal end side of the balloon and configured to introduce fluid to the balloon. The balloon includes a body portion having a first wall thickness, a cylindrical tail portion arranged on a proximal end side of the body portion and connected to the sheath, a cone portion located between the body portion and the tail portion, and a thick portion forming a second wall thickness larger than the first wall thickness. The thick portion whose distal end is arranged in the cone portion and whose proximal end is arranged in the tail portion.

Balloon-equipped treatment tool for endoscope, and method of folding balloon-equipped treatment tool for endoscope

The present invention provides a compound having a dihydropyran structure, a method of producing a compound having a dihydropyran structure, a method of producing Pre-SMTP, a method of producing a group of SMTPs, and a pharmaceutical composition. The compound having a dihydropyran structure can be a useful intermediate in the chemically producing a group of Pre-SMTP and SMTP. Specifically, the compound having a dihydropyran structure is represented by the following formula (), wherein: RSi is a silyl group selected from TMS: trimethylsilyl, TES: triethysilyl, TBS (TBDMS): tert-butyldimethylsil, TIPS: triisopropylsilyl, TBDPS: tert-butyldiphenylsilyl, X is selected from COOH, CHO, and &#x2014;CH&#x2550;C(CH)&#x2014;(CH)&#x2014;CH&#x2550;C(CH). 

Chemical method of producing SMTP groups or SMTP-7 and intermediates used in the method

A single crystalline aluminum nitride laminated substrate comprising a single crystalline &#x3b1;-AlOsubstrate such as a sapphire substrate, an aluminum oxynitride layer formed on the substrate and a single crystalline aluminum nitride film as the outermost layer, wherein the dislocation density in the single crystalline aluminum nitride is 10/cmor less. The above single crystalline aluminum nitride laminated substrate is formed by nitriding the substrate by heating in the presence of carbon, nitrogen and carbon monoxide. The above single crystalline aluminum nitride film has a law dislocation density, little lattice mismatching and excellent crystallinity. A Group III element nitride film having excellent luminous efficiency can be formed on this aluminum nitride film. The above laminated substrate is used in a base substrate for a Group III element nitride film, a light emitting device and a surface acoustic wave device.

Single crystalline aluminum nitride film, method of forming the same, base substrate for group III element nitride film, light emitting device and surface acoustic wave device

A process for preparing a therapeutic agent characterized by preculturing human amnion cells isolated from human amnion by trypsinization or human amnion cells obtained by subculturing the isolated cells in a medium containing calf or bovine fetal serum at least one time for 1 to 5 days to form a monolayer, removing the medium, adding a medium containing 0.5 to 20 mg of human serum albumin per 1 ml of medium thereto and culturing it for 3 to 6 days, dialyzing the culture liquid against diluted buffer or water, and filtering the dialyzed culture liquid through a bacterial filter thereby obtaining a germ free liquid agent.

Process for preparing a curing agent for myelogenic leukemia

Process for preparing a therapeutic agent

Growing community of inventors

Tokyo, Japan

Kazuhiro Nagata